Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics

Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.

The word Cancer hidden in a strand of DNA

Exact Sciences Corp. has entered into an agreement to buy Thrive Earlier Detection Corp. for cash and stock consideration of up to $2.15 billion in a move to strengthen its position in the emerging multi-cancer screening market.

Exact, the company behind the Cologuard stool-based colorectal cancer test has been upfront about its aspirations to be leader in...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Deals

More from Business